This medicinal product is for diagnostic use only
PYLCLARITM is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:
Detailed recommendations for the use of this product can be found in the Summary of Product Characteristics (SmPC).
*The Marketing Authorization has been granted for PYLCLARITM in all EU members. PYLCLARITM might not be commercially available yet in your country
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See SmPC, section 4.8 for how to report adverse reactions.
The information on this page is intended for use by healthcare providers only. By continuing, you automatically confirm that you are a professional healthcare provider in a European country.